- BioNTech’s Dr. Ugur Sahin topped Fierce Pharma‘s 2024 list with $287 million, while Pfizer’s Albert Bourla ($24.6 million) and Eli Lilly’s David Ricks ($29.2 million) ranked among the highest-paid, reflecting booming drug sales (e.g., weight-loss drugs, COVID-19 vaccines).
- Executives’ multimillion-dollar payouts contrast sharply with soaring prescription costs, eroding public trust as patients struggle to afford medications like insulin.
- Major firms (Merck, Bristol Myers Squibb, AstraZeneca, J&J) are suing to block Medicare price negotiations, while industry lobbying fights to maintain high drug prices despite evidence of greater spending on stock buybacks than R&D.
- Executives at Pfizer, Moderna and J&J cashed out $250 million in stocks post-Operation Warp Speed, while Moderna’s CEO earned $392 million in 2023 despite missing the 2024 list.
- Critics highlight a rigged system where executive bonuses and corporate profits take priority over affordable healthcare, widening the gap between boardroom gains and patient hardships.
(Natural News)—As Big Pharma executives continue to amass staggering fortunes, patients face soaring prescription costs and dwindling trust in an industry that profits from lifesaving medicines.
Fierce Pharma released its Top 10 highest-paid pharmaceutical executives list for 2024 on Monday, June 16. BioNTech’s Dr. Ugur Sahin topped the list at $287 million – nearly 10 times more than his closest competitor. Eli Lilly’s David Ricks, who landed on No. 2, secured $29.2 million amid booming sales of weight-loss drugs Zepbound and Mounjaro.
Pfizer CEO Albert Bourla landed on No. 3 in the list, with his earnings rebounding to $24.6 million after the Wuhan coronavirus (COVID-19) slump. AstraZeneca’s Pascal Soriot, who pocketed $22.9 million despite investor backlash over bonus hikes, was in ninth place.
The eye-popping figures compiled by Fierce Pharma revealed an elite class of executives whose paychecks dwarf the average American’s lifetime earnings. They also underscored a widening chasm between corporate profits and public health.
While Sahin’s windfall came from cashing out stock options tied to BioNTech’s pandemic-era mRNA vaccine success, Moderna’s Stephane Bancel was conspicuously absent from the list due to his company’s smaller market cap. He remains formidable despite his absence on the 2024 list after raking in $392 million in 2023. (Related: GREED PARADE: Moderna plans to sell COVID-19 vaccine for up to $130 per dose – more than 8 times its initial price of $15.25 per dose.)
Meanwhile, Johnson & Johnson’s Joaquin Duato saw his pay drop 14 percent to $24.6 million – putting him on No. 5 in the list. J&J remains embroiled in costly talc litigation and lawsuits over its discontinued COVID-19 vaccine linked to fatal blood clots.
Big Pharma prioritizes PROFITS over people
Critics argue these payouts reflect a system rigged in favor of executives, even as drugmakers lobby aggressively against Medicare price negotiations. Merck and Bristol Myers Squibb, whose CEOs earned $23.2 million (No. 7 on the list) and $18.8 million (No. 10) respectively, are among those suing the government to block lower drug costs.
AstraZeneca and J&J have joined the legal battle, while the Pharmaceutical Research and Manufacturers of America – the industry’s lobbying arm – fights to preserve pricing power. Meanwhile, research shows top firms spend more on stock buybacks and dividends than on R&D, debunking claims that high prices fund innovation.
The trend isn’t new. During the pandemic, executives at Pfizer, Moderna and J&J cashed out $250 million in stocks within six months of Operation Warp Speed, as per watchdog group Accountable.US. Bourla’s net worth, estimated at $35.6 million, places him in the wealthiest one percent of Americans – a stark contrast to the millions rationing insulin or skipping doses due to cost.
As the pharmaceutical industry braces for more scrutiny, one question lingers. When will the pursuit of profit align with the promise of affordable healthcare? For now, the gap between boardroom bonuses and patients’ bills has never been wider.
Head over to BigPharmaNews.com for more similar stories. Watch AstraZeneca CEO Pascal Soirot agreeing with U.S. President Donald Trump’s order to lower drug prices in this Fox Business interview.
This video is from the NewsClips channel on Brighteon.com.
More related stories:
- Coronavirus pandemic creates 9 new Big Pharma billionaires.
- Pfizer CEO Albert Bourla now HIGHEST PAID pharma executive in the world.
- Heads of vaccine makers Moderna, BioNTech included in list of COVID-19 billionaires.
Sources include:
Two Storms, One Harvest
Every food crisis in living memory has been a one-shock event. The 2008 price spike was a commodity bubble. The 2020 shortages were a logistics failure. The 2022 grain scare was a war on one exporter’s ports. Each time, the system bent, adjusted, and recovered, and each time the experts assured us afterward that global markets are simply too big and too diversified to fail.
What nobody in Washington seems eager to discuss is that 2026 is shaping up to be something the modern food system has never actually faced. Two independent shocks, one climatic and one geopolitical, are converging on the same harvest cycle at the same time. Not sequentially. Simultaneously.
Start with the weather. The Pacific Ocean is currently building toward what forecasters now openly call a record event. NOAA’s Climate Prediction Center puts the odds of at least a strong El Niño near 88 percent, with roughly two in three odds it reaches “very strong” status, the tier reserved for perhaps three or four events in the entire satellite era. Every major global model now projects a median peak in Super El Niño territory, and most of them project it exceeding the 2015-16 event, which until now held the modern record. Sea surface anomalies were already brushing the super threshold in mid-July, months before these events normally peak. The atmosphere has already shifted into El Niño mode, and the event is forecast to crest in late fall and early winter.
This is not about “climate change.” It’s about the standard cycles of weather, and the cycle we’re currently in is one that has likely devastated societies in the past. We’re better prepared as a society today, but not all Americans are equally prepared.
Serious households have started doing the quiet math on their own. Grocery bills tell part of the story, and the forecast maps tell the rest, which is why long-term food storage has moved from fringe hobby to mainstream line item in the family budget, with established suppliers like Heaven’s Harvest seeing demand from people who five years ago would have rolled their eyes at the idea. That instinct is not paranoia. It is pattern recognition, and the pattern is worth walking through carefully.
Editor’s Note: Heaven’s Harvest IS a sponsor, but the warnings of this article are real and would be written even if we didn’t have a survival food sponsor. With that said, those who take advantage of what they offer can use promo code “Patriot” for 15% off.
The Fertilizer Clock Is Already Running
While the Pacific warms, the second shock has been unfolding in the Strait of Hormuz. The conflict with Iran turned the world’s most important energy chokepoint into a contested waterway, and the consequences reach far beyond the gas pump. Roughly a third of global fertilizer trade moves through Hormuz, and the disruption sent urea prices up 86 percent year over year by March, with a 53 percent jump in a single month.
The World Bank projects energy prices rising about 24 percent in 2026 and fertilizer about 31 percent. By its own accounting, fertilizer prices ran 35 percent higher in the first five months of this year than the same period last year.
Here is the mechanism the nightly news will not explain. Fertilizer is not a grocery item. It is a time-delayed input. The nitrogen a farmer in Iowa or Punjab could not afford to apply this spring does not show up as a problem this spring. It shows up as a thinner harvest six to twelve months later.
The World Bank’s own food security brief concedes that the effects of reduced applications earlier this season “are likely to become visible only later in harvest outcomes.” Translate that from institutional language into plain English and it means this. The damage is already done, it is already in the ground, and we are simply waiting for it to arrive on the shelf.
Now check the calendar. Six to twelve months from the spring planting season lands us squarely in late 2026 and early 2027. Which is precisely when the strongest El Niño in the instrumental record is forecast to peak, bringing its signature droughts to Southeast Asia, Australia, southern Africa, northern Brazil, and South Asia, the very regions that grow the world’s rice, sugar, and oilseeds.
The World Bank warns openly that a strong El Niño “could disrupt multiple crop belts simultaneously” on top of the conflict-driven input costs. Their baseline projection assumes the Middle East disruptions ease by autumn. What in the last two years of Middle East history suggests that assumption is safe?
The System Has No Slack Left
The comfortable answer is that global markets always adjust. But adjustment requires slack, and the slack is gone. Global cereal production is expected to decline from last year’s records even before El Niño does its work. The UN World Food Programme, hardly a den of right-wing preppers, is calling this the most significant disruption to its supply chains since Covid and the invasion of Ukraine, and its supply chain director put the stakes bluntly.
Today’s supply chain challenges are tomorrow’s hunger crisis.
There is also a political dimension that markets cannot price. When food gets scarce, governments do not behave like economists. They behave like politicians. Export bans, hoarding mandates, and panic buying at the national level turned the modest rice shortfall of 2008 into a global crisis, and analysts are already warning that import-dependent nations are the first dominoes.
The 2015-16 Super El Niño, a far weaker event than what is now forecast, threw tens of millions into food stress across Africa and Asia. This one is projected to be stronger, and it arrives with fertilizer already rationed by price and shipping lanes already contested by missiles.
What Joseph Knew
Scripture does not treat preparation for lean years as faithlessness. It treats it as wisdom delivered in advance to those willing to act on it.
Behold, there come seven years of great plenty throughout all the land of Egypt: And there shall arise after them seven years of famine; and all the plenty shall be forgotten in the land of Egypt.
Joseph did not respond to that warning with a hashtag or a committee. He stored grain during the years of abundance, and when the famine came, Egypt stood while its neighbors begged. The lesson is not that famine is certain. It is that the time to prepare is precisely when preparation still looks optional.
Nobody who filled a pantry in a year of plenty has ever regretted it, and nobody standing in an empty aisle has ever been glad he waited for certainty.
None of this calls for panic, and panic is the enemy of sound judgment anyway. It calls for the same unglamorous prudence our grandparents considered ordinary. Keep some cash margin, know your local growers, and put real food in deep storage while it is cheap and available, because the entire arc of this story is that cheap and available is a closing window.
Families looking for a straightforward place to start can visit Heaven’s Harvest and use promo code Patriot for 15 percent off long-term storable food. The forecasts may yet soften, the strait may yet reopen, and we should pray they do. But hope is a fine thing to hold and a foolish thing to eat.
